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The identification of potential new anti-tubercular chemotherapeutics is paramount due to the
recent emergence of extensively drug-resistant strains of Mycobacterium tuberculosis (XDR-TB).
Libraries of NAS-21 and NAS-91 analogues were synthesized and evaluated for their whole-cell
activity against Mycobacterium bovis BCG. NAS-21 analogues 1 and 2 demonstrated enhanced
whole-cell activity in comparison to the parental compound, and an M. bovis BCG strain
overexpressing the dehydratase enzyme Rv0636 was resistant to these analogues. NAS-91
analogues with ortho-modifications gave enhanced whole-cell activity. However, extension with
biphenyl modifications compromised the whole-cell activities of both NAS-21 and NAS-91
analogues. Interestingly, both libraries demonstrated in vitro activity against fatty acid synthase II
(FAS-II) but not FAS-I in cell-free extracts. In in vitro assays of FAS-II inhibition, NAS-21
analogues 4 and 5 had IC50 values of 28 and 19 mg ml
”1, respectively, for the control M. bovis
strain, and the M. bovis BCG strain overexpressing Rv0636 showed a marked increase in
resistance. In contrast, NAS-91 analogues demonstrated moderate in vitro activity, although
increased resistance was again observed in FAS-II activity assays with the Rv0636-
overexpressing strain. Fatty acid methyl ester (FAME) and mycolic acid methyl ester (MAME)
analysis of M. bovis BCG and the Rv0636-overexpressing strain revealed that the effect of the
drug was relieved in the overexpressing strain, further implicating and potentially identifying
Rv0636 as the target for these known FabZ dehydratase inhibitors. This study has identified
candidates for further development as drug therapeutics against the mycobacterial FAS-II
dehydratase enzyme.
INTRODUCTION
The emergence of multi-drug resistant Mycobacterium
tuberculosis (MDR-TB) (Kaye & Frieden, 1996) and the
more recent identification of extensively drug-resistant M.
tuberculosis (XDR-TB) (CDC, 2006) has highlighted the
need for new TB drugs. Mycolic acids (C60–C90) are vital
cell wall components of M. tuberculosis which form a lipid-
rich permeability barrier. Currently, isoniazid represents
the mainstay for chemotherapy against TB; it is known to
target mycolic acid biosynthesis (Banerjee et al., 1994).
Mycolic acid biosynthesis involves both fatty acid synthase-
I (FAS-I) and fatty acid synthase-II (FAS-II), with FAS-II
being uniquely found in bacteria, plants and apicomplexan
parasites, such as Plasmodium (Takayama et al., 2005;
Waller et al., 2003). M. tuberculosis FAS-I catalyses de novo
synthesis of intermediate-length (principally C16 and C24)
fatty acids. FAS-II, however, is incapable of de novo fatty
acid synthesis and accepts short-chain (C16) acyl-CoA
primers from FAS-I via a condensation reaction carried out
by b-ketoacyl-ACP synthase III (mtFabH) (Brown et al.,
2005; Choi et al., 2000). This newly formed b-ketoacyl-
ACP is reduced by a b-ketoacyl-ACP reductase (MabA)
(Banerjee et al., 1998) to form a b-hydroxyl-acyl-ACP
intermediate. The product is then dehydrated by b-
hydroxyacyl-ACP dehydratase (designated FabA and
FabZ in Escherichia coli), followed by further reduction
with the enoyl-ACP reductase, InhA, to complete the FAS-
II cycle (Banerjee et al., 1994; Kikuchi & Kusaka, 1984).
Subsequent FAS-II cycles are initiated by the acyl-ACP-
primed b-ketoacyl-ACP synthases KasA and KasB, respect-
ively (Kremer et al., 2000; Mdluli et al., 1998; Schaeffer et
al., 2001), to afford a meromycolic acid (C56), which is
then condensed with a C26 fatty acid (Gande et al., 2004;
Portevin et al., 2005; Takayama et al., 2005). The
oxomycolic acid intermediate is then reduced to form the
mature mycolic acid (Lea-Smith et al., 2007).
Abbreviations: ACP, acyl carrier protein; FAMEs/MAMEs, fatty/mycolic
acid methyl esters; FAS, fatty acid synthase; MeOH, methanol; MTBE,
methyl tert-butyl ether; NaOMe, sodium methoxide; TB, tuberculosis.
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The dehydratase enzymes FabZ and FabA have been
extensively studied in both E. coli and Plasmodium
falciparum (Leesong et al., 1996; Sharma et al., 2003).
Both FabZ and FabA catalyse the dehydration of the b-
hydroxylacyl-ACP to a trans-2-enoyl ACP in the third step
of fatty acid elongation. In addition to performing the
dehydration step, FabA has the ability to isomerize trans-2-
to cis-3-decanoyl-ACP (Fig. 1), as an essential step in the
formation of unsaturated fatty acids in E. coli (Kass &
Bloch, 1967; Kass et al., 1967). The pivotal role played by
FabZ and FabA makes them good potential drug targets
against M. tuberculosis. The identification of the key FAS-II
dehydration step in mycobacteria has remained an enigma
until very recently (Sacco et al., 2007).
In an attempt to establish whether Rv0636 represented the
potential dehydratase candidate, overexpression studies
were performed in M. bovis BCG against a series of
flavonoid inhibitors known to target FabZ (Brown et al.,
2007b). Of the five flavonoids tested, four were found to be
active againstM. bovis BCG with MICs ranging from 150 to
220 mM, the most potent being butein. The activity of the
flavonoids against the hypothesized gene product Rv0636
indicated that the overexpression in M. bovis BCG
conferred resistance to butein and isoliquirtigenin
(Brown et al., 2007b). The data suggested that the
flavonoids are inhibitors of mycobacterial FAS-II and in
particular Rv0636, reiterating the potential candidacy of
this gene product as the dehydratase enzyme of the FAS-II
in M. tuberculosis.
Sacco et al. (2007) had independently demonstrated that
the Rv0635–Rv0637 operon encoded dehydratase activity.
The recombinant expression of the candidate protein
cluster, Rv0635-Rv0636-Rv0637, led to the formation of
two heterodimers, Rv0635-Rv0636 (HadAB) and Rv0636-
Rv0637 (HadBC), which were shown to also occur in
Mycobacterium smegmatis (Sacco et al., 2007). Both
heterodimers exhibited the enzymic properties expected
for mycobacterial FAS-II dehydratases, including a marked
specificity for both long-chain (.C12) and ACP-linked
substrates (Sacco et al., 2007). Furthermore, the authors of
this study were able to show the function of Rv0636 or
HadAB/ HadBC as a b-hydroxyacyl dehydratase when
coupled with MabA and InhA enzymes from M. tuber-
culosis FAS-II.
Further research into potential dehydratase inhibitors has
yielded the identification of NAS-21 and NAS-91, which
have been shown to target b-hydroxyacyl-ACP dehydratase
FabZ of P. falciparum (Sharma et al., 2003). A decrease in
the rate of enzyme activity was observed in the presence of
both NAS-21 and NAS-91 using spectrometric and HPLC
methods. The authors of that study also showed that the
incorporation of [2-14C]malonyl-CoA into fatty acids in
cell-free extracts of P. falciparum was inhibited to different
extents by NAS-21 and NAS-91. The incorporation of
[1, 2-14C]acetic acid into fatty acids was reduced by 26 and
46%, respectively, in the presence of 10 mM NAS-21 and
NAS-91. To investigate the potential anti-mycobacterial
therapeutic activity of NAS-21 and NAS-91, we synthesized
a library of these FabZ inhibitors. Using a similar strategy
to that previously presented (Brown et al., 2007b), we
evaluated the analogues for their whole-cell activity against
M. bovis BCG and an Rv0636-overexpressing M. bovis BCG
strain, and and their in vitro activity against FAS-I and
FAS-II in cell-free assays using M. smegmatis extracts.
METHODS
Synthesis of NAS-21 analogues. A series of NAS-21 analogues
were developed using a previously described method (Sharma et al.,
2003) (Scheme 1). In brief, acetophenone derivatives were condensed
with ethyl trifluoroacetate in the presence of 25% NaOMe (in
MeOH) and methyl-tert-butyl ether. Diversity was introduced into
these reactions using a variety of commercially available acetophe-
none derivatives, yielding analogues 1–6 (Table 1). Biphenyl
analogues 7–9 were developed via Suzuki coupling of 4-iodoaceto-
phenone with aryl boronic acid derivatives. The product was then
subjected to treatment with ethyl trifluoroacetate, 25% NaOMe in
MeOH and MTBE (Scheme 1) to yield the desired analogues 7–9. An
example of the Suzuki coupling reaction for analogue 7 is as follows.
4-Iodoacetophenone (100 mg, 0.292 mmol, 1 eq.), ethylene glycol
dimethyl ether (3 ml), aqueous Na2CO3 (0.5 ml, 1 M) and 4-
fluorophenylboronic acid (48.97 mg, 0.37 mmol, 1.2 eq.) in a round-
bottom flask was degassed for 10 min. Bis(triphenylphosphine)
palladium chloride (8 mg, 761023, 5 mol%) was then added and
the mixture was heated under reflux for 6 h. The mixture was
partitioned between water (10 ml) and ethyl acetate (10 ml) and
separated. The aqueous layer was acidified to pH 2 with dilute
hydrochloric acid (2 M) and the product was extracted with ethyl
acetate (2610 ml). The organic layers were combined, washed with
saturated brine (3610 ml), dried and reduced to give the crude
product. Purification was achieved via two separate silica gel columns.
The first column used chloroform in methanol (95 : 5, v/v) as eluant
and the second column used ethyl acetate in petroleum ether (35 : 65).
The title analogue gave a white solid in 78% yield (62 mg). 1H NMR
(CDCl3, 300 MHz) dH: 2.60 (s, 3H, CH3, H-14), 7.05 (d, 2H, H-5, H-
7, J58.5 Hz), 7.50 (d, 2H, H-4, H-8, J58.5 Hz), 7.60 (d, 2H, H-3, H-
9, J58.0 Hz), 7.95 (d, 2H, H-2, H-10, J58.0 Hz). 13C NMR (CDCl3,
75 MHz) dC: 23.8 (C-14), 116.0, 127.4, 129.8 (C-2, 3, 4, 5, 7, 8, 9, 10),
132.0 (C-12), 136.7 (C-1), 142.0 (C-11), 168.4 (C-6), 195.6 (C-13);
m/z (EI) 214.2 [M+] (100%); HRMS calculated for C14H11FO [M
+]
214.2319 found 214.2327.
Fig. 1. Dehydration and isomerization of 3-
hydroxydecanoyl-ACP by E. coli FabA.
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Synthesis of NAS-91 analogues. NAS-91 was synthesized as
described by Sharma et al. (2003). The reaction involves the coupling
of 2-bromo-4-chlorophenol with 5-chloro-8-hydroxyquinolone,
using caesium carbonate, copper (I) chloride (0.5 eq.) and N-
methylpyrrolidinone as the solvent (Scheme 2) (Ullmann & Sponagel,
1905). An alternative method was developed to synthesize the
remaining NAS-91 analogues in Table 2. A linker arm was introduced
into 5-chloro-8-hydroxyquinolone by reacting it with benzyl bromide
derivatives under basic conditions (Scheme 3). Diversity was
introduced into this library by utilizing a variety of commercially
available benzyl bromide derivatives. This method was employed to
generate a library of seven novel NAS-91 analogues (10–16) (Table 2),
which contain a methylene linker arm connected to the oxygen of 5-
chloro-8-hydroxyquinolone. As an example, analogue 10 was
synthesized as follows. 5-Chloro-8-hydroxyquinolone (500 mg,
2.78 mmol, 1 eq.) was dissolved in 5 ml dimethylformamide. To this
was added caesium carbonate (452 mg, 1.39 mmol, 0.5 eq.). After
20 min of mixing at room temperature, benzyl bromide (0.37 ml,
3.06 mmol, 1.1 eq.) was added dropwise and the reaction was stirred
at room temperature overnight. The reaction mixture was quenched
with water. The organic layer was extracted with ethyl acetate, washed
with water and brine, dried and reduced in vacuo to yield the crude
product. The title analogue 10 was recrystallized to give a white solid
in 85% yield (635 mg). 1H NMR (CDCl3, 300 MHz) dH: 5.35 (s, 2H,
CH2, H-11), 6.85 (d, 1H, H-7, J58.44 Hz), 7.15–7.45 (m, 4H, H-12,
H-14, H-15, H-16), 7.48–7.50 (m, 3H, H-3, H-6, H-13), 8.40 (d, 1H,
H-4, J58.54 Hz), 8.90 (d, 1H, H-2, J54.17 Hz). 13C NMR (CDCl3,
75 MHz) dC: 68.9 (C-11), 107.8 (C-7), 120.4 (C-3), 124.3 (C-5), 124.5
(C-6), 125.2 (C-13, C-17), 126.1, 126.8, 127.2 (C-15, C-16, C-17),
130.8 (C-4), 134.5 (C-12), 138.1 (C-9), 147.8 (C-2), 153.2 (C-8);
3019.6m, 1638.3m, 1215.6s; m/z (EI) 369.06 [M+] (30%), 91.00
[C6H6CH2
+] (100%); HRMS calculated for C16H12ClNO [M
+]
269.0607 found 269.0603.
Bacterial strains, growth conditions and MIC99 determination.
All reagents were of assay grade and purchased from Sigma-Aldrich.
Overexpression of pVV16-Rv0636 (Brown et al., 2007b) was
conducted inM. bovis BCG on Middlebrook 7H10 agar supplemented
with oleic-albumin-dextrose-catalase (OADC) enrichment (BD and
Company) and containing 25 mg kanamycin ml21 and 50 mg
hygromycin ml21 (Kremer et al., 1995). Liquid cultures of M. bovis
BCG were grown at 37 uC in Sauton’s medium containing 25 mg
kanamycin ml21 and 50 mg hygromycin ml21. MIC99 values of NAS
analogues against M. bovis BCG/pVV16 and M. bovis BCG/pVV16-
Rv0636 were determined by Alamar Blue as described previously
using the manufacturer’s protocol (Celltiter-Blue; Promega) followed
by MIC99 calculations over the concentration range 0–200 mg ml
21
(Franzblau et al., 1998).
Determination of the whole-cell effects of NAS analogues on
fatty acid and mycolic acid synthesis.M. bovis BCG cultures were
grown to OD600 0.4 in the presence of 0.25% Tween 80. The NAS
analogues were added at various concentrations followed by
incubation at 37 uC for 8 h and then 1 mCi (37 kBq) ml21
[1,2-14C]acetate (50–62 mCi mmol21, GE Healthcare, Amersham
Bioscience) was added to the cultures, followed by further incubation
at 37 uC for 16 h. The 14C-labelled cells were harvested by
centrifugation at 2000 g followed by washing with PBS. The 14C-
labelled control and NAS-treated cells were then subjected to alkaline
hydrolysis using 5% aqueous tetrabutylammonium hydroxide at
100 uC overnight, followed by the addition of 4 ml CH2Cl2, 500 ml
CH3I and 2 ml water, followed by mixing for 30 min. The upper
aqueous phase was discarded following centrifugation and the lower
organic phase washed three times with water and evaporated to
dryness. The resulting fatty acid methyl esters (FAMEs) and mycolic
acid methyl esters (MAMEs) were redissolved in diethyl ether, and the
supernatant was again removed after centrifugation and evaporated to
dryness and redissolved in 200 ml CH2Cl2. An equivalent aliquot
(20 ml) or equal counts (50 000 c.p.m.) of the resulting solution of
FAMEs and MAMEs was subjected to TLC using silica gel plates (5735
silica gel 60F254; Merck), developed in petroleum ether/acetone
(95 : 5). Autoradiograms were produced by overnight exposure to
Kodak X-Omat AR film to reveal 14C-labelled FAMEs and MAMEs.
Alternatively, free lipids were extracted from the 14C-labelled cells and
crude lipids examined by TLC for PGL and phospholipid synthesis
using the procedures of Dobson et al. (1985).
Preparation of cytosolic fractions, and FAS-I and FAS-II
assays. Cytosolic extracts, enriched for FAS-I and FAS-II using
ammonium sulphate precipitation, of M. smegmatis mc2155/pVV16
and M. smegmatis mc2155/pVV16-Rv0636 (approx. 10 g) were
prepared as described previously (Kremer et al., 2002a). The final
extract containing the FAS-I and FAS-II activities was dissolved in
5 ml 50 mM MOPS pH 7.9, 5 mM b-mercaptoethanol, 10 mM
MgCl2. Protein concentrations were determined using the BCA
protein assay reagent kit (Pierce). FAS-I and FAS-II assays were
conducted as previously described using the 40–80% ammonium
sulfate fraction (Kremer et al., 2002b; Slayden et al., 1996).
RESULTS AND DISCUSSION
Biological evaluation of NAS-21 analogues
NAS-21 has been shown to target the b-hydroxylacyl-ACP
dehydratase FabZ of P. falciparum (Sharma et al., 2003).
The mycobacterial FabZ (Rv0635–637) is a potentially
attractive target for such an inhibitor; therefore we sought
to synthesize and evaluate NAS-21 analogues against M.
bovis BCG, which possesses a similar drug profile to M.
tuberculosis in terms of sensitivity (Larsen et al., 2002;
Vilcheze et al., 2005). The results of the whole-cell analysis
of NAS-21 analogues against M. bovis BCG pVV16 and M.
bovis BCG/pVV16-Rv0636, which overexpresses Rv0636,
are shown in Table 1. It is clearly evident that the
Scheme 1. Method for production of NAS-21 analogues.
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COCH2COCF3 group plays a central role in the activity of
NAS-21 analogues, because the simple conversion of this
group to the COCH3 functionality resulted in the
inactivation of the compounds (MIC99.250 mg ml
21)
(data not shown). Two possible explanations for this
observed decrease in activity are (i) the di-keto nature of
the analogue may mimic the b-keto substrate utilized in
FAS-II and may act as a competitive inhibitor or (ii) the
presence of the CF3 group may stabilize the formation of
the keto–enol tautomer of these analogues, which may
increase the interaction of the drug with the enzyme’s
active site. Extension in the para-position of the aromatic
ring in NAS-21 resulted in analogues with a significant
reduction in activity (Table 1). This is demonstrated by the
NAS analogues inhibit mycobacterial FAS-II dehydratase
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effects of (i) the simple modification of the methyl group in 4 to an ethyl group in 5 and (ii) the introduction of a
Scheme 2. Method for production of NAS-91
analogues.
V. Bhowruth, A. K. Brown and G. S. Besra
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biphenyl group (7–9), thus indicating that modifications
extending in this position are not well tolerated.
Comparable whole-cell activity of the parent drug NAS-
21 and analogues 1, 2 and 4 was demonstrated against M.
bovis BCG/pVV16. A significant decrease in whole-cell
activity against the Rv0636-overexpressing M. bovis BCG
strain was also observed, suggesting that the product of this
gene may represent the cellular target for NAS-21 and
analogues 1, 2 and 4.
Effects of NAS-21 analogues on activity of FAS-I
and FAS-II in cell-free extracts
To further evaluate the biological properties of NAS-21
analogues and to investigate their potential target, Rv0636,
a series of in vitro FAS-I and FAS-II assays were performed
on crude cell-free extracts of M. smegmatis as previously
described by Slayden et al. (1996). The analysis was
performed on extracts isolated from both M. smegmatis/
pVV16 and M. smegmatis/pVV16-Rv0636. The activity of
each analogue was measured by the incorporation of
radiolabel into extractable lipids. Specific assays were
utilized by using priming units in the form of two different
fatty acyl-CoAs, either acetyl-CoA or palmitoyl-CoA, for
FAS-I or FAS-II, respectively. In both cases [1, 2-
14C]malonyl-CoA was utilized as the radiolabelled carbon
donor. In the case of FAS-I, [1,2-14C]malonyl-CoA coupled
with acetyl-CoA to form short-chain fatty acids. However,
in the case of FAS-II, [1,2-14C]malonyl-CoA is transacylated
by mtFabD to form [1,2-14C]malonyl-AcpM, which is
subsequently used for the initiation of FAS-II by mtFabH
(Choi et al., 2000). AcpM supplementation in the FAS-II
assays drives the reaction towards the production of
[1,2-14C]malonyl-AcpM. Inhibition (IC50) values were
determined by varying the concentrations of the drug
and by measuring the incorporation of radioactivity into
extractable lipids. The results of the crude cell-free extract
assay revealed that none of the analogues synthesized
inhibited FAS-I (data not shown). Encouragingly, an
increased activity was observed for most analogues against
FAS-II (Table 1). Analogues 1–6 gave good in vitro activity
against the cell-free M. smegmatis pVV16 extracts of FAS-
II. In particular 3, 4 and 5 gave IC50 values of 35, 28 and
19 mg ml21, respectively, against the M. smegmatis/pVV16
FAS-II extract. An increase in resistance was also observed
for M. smegmatis/pVV16-Rv0636, further suggesting
Rv0636 to be a potential target of the analogues.
Interestingly, the whole-cell analysis of analogues 3 and 5
gave very poor activities (Table 1), indicating that these
modifications affect the permeability of the drug across the
cell wall or that they are modified prior to reaching their
target. It was also interesting that analogues 1 and 2, which
gave the most pronounced effects against whole cells of M.
bovis BCG/pVV16 and M. bovis BCG/pVV16-Rv0636, did
not give the same marked response compared to 4 and 5 in
relation to FAS-II inhibition with the same strains
(Table 1). Analogues 7–9 were inactive against whole cells;
however, moderate activity was observed in FAS-II assays
(Table 1), implying that cell permeability may be a
contributing factor towards the lack of whole-cell activity
of these biphenyl-containing analogues.
Biological evaluation of NAS-91 analogues
NAS-91 showed poor whole-cell activity against both M.
bovis BCG/pVV16 and M. bovis BCG/pVV16-Rv0636 and
no inhibition was observed even at high concentrations
(.250 mg ml21) (Table 2). The observed poor inhibition
of M. bovis BCG growth was surprising since Gratraud et
al. (2008) recently reported an MIC value of 25 mg ml21
against M. bovis BCG for NAS-91, although the MIC values
reported for NAS-21 (50 mg ml21) by Gratraud et al.
(2008) are similar to the values (63 mg ml21) reported in
this study. A key feature of note in the studies by Gratraud
et al. (2008) was that the MIC values were determined on
Middlebrook 7H11 agar plates by visualizing plaques
following serial dilution. In contrast, in this present study,
MIC values for NAS-91 (as well as NAS-21) were
determined using the more established and sensitive
Alamar Blue method (Franzblau et al., 1998) in Sauton’s
liquid medium. It is clear that MIC values for NAS-91 in
particular are different on liquid and solid media. This is
not totally surprising since similar observations have been
reported for drug inhibition of mycobacterial strains. For
instance, M. smegmatis is sensitive to econazole and
clotrimazole on LB solid agar plates, with MIC values of
2 and 0.5 mg ml21, respectively (Burguiere et al., 2005).
However, when M. smegmatis is cultured in Sauton’s liquid
medium, the MIC values are higher than those determined
on agar plates, with econazole at 20 mg ml21 (10-fold
higher) and clotrimazole at 15 mg ml21 (30-fold higher),
respectively. Interestingly, it is clear that a concentration of
100 mg ml21 of NAS-91 in liquid media is only partially
inhibiting mycolate synthesis (50%) in the Gratraud et al.
(2008) study, which is at four times the MIC value on solid
media. This is further evidence for the MIC value for NAS-
91 being different on solid and liquid media.
Scheme 3. Method for adding a linker arm to
5-chloro-8-hydroxyquinolone.
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Analogues 13–16 demonstrated significantly improved
whole-cell activity in comparison to NAS-91. The simple
introduction of a methyl modification in analogue 15
resulted in the most improved whole-cell activity, with an
MIC99 value of 18 mg ml
21 against M. bovis BCG/pVV16.
Encouragingly, resistance was shown against analogue 15
when M. bovis BCG/pVV16-Rv0636 was used, with an
increase in MIC99 to 100 mg ml
21. Structurally, analogues
13 and 14 indicate that there is more scope to extend the
modification in the ortho-position by two or more carbons.
Analogues 10 and 11 were primarily developed to assess the
feasibility of introducing a linker arm into the analogues
whilst changing the functionalities on the aromatic ring. As
indicated in Table 2, the low biological activity of these
analogues was comparable to that of NAS-91. Initially it
was felt that the linker arm might have compromised
activity by reorientating the analogue within the active site,
thus affecting its interactions with the target. However, as
observed with analogues 13–16, modifications in the ortho-
position of the aromatic ring greatly increase the potency
of this analogue, suggesting it is the nature of the
modification on 10 and 11 which has compromised their
whole-cell activity. From the activities observed with
analogues 13–16 it is evident that the hydroxyl group of
the secondary aromatic functionality does not play an
important part in the protein–drug interaction, as activity
was still observed in these analogues. Finally, the
introduction of a second aromatic group in the para-
position (12) compromised the whole-cell activity against
both M. bovis BCG/pVV16 and M. bovis BCG/pVV16-
Rv0636. This initial study suggests that there is limited
scope to further extend in the para-position with a second
aromatic ring; however, this requires verification by
formulating a more comprehensive library.
Effects of NAS-91 analogues on activity of FAS-I
and FAS-II in cell-free extracts
To further evaluate the activities of the NAS-91 analogues,
a series of in vitro FAS-I and FAS-II assays were performed
on crude cell-free extracts of M. smegmatis. As with the
NAS-21 analogues, the crude M. smegmatis cell-free FAS-I
assays revealed that none of the analogues inhibited FAS-I
(data not shown). Analogues 10 and 12 demonstrated
similar effects to NAS-91 against FAS-II activity in M.
smegmatis cell-free extracts (Table 2). Encouragingly,
analogues 11 and 13–15 gave a marked increase in in vitro
activity against FAS-II, and extracts from M. smegmatis/
Fig. 2. TLC-autoradiography ofM. bovis BCG
FAMEs and MAMEs after NAS-21 and NAS-
91 analogue treatment. (A) NAS-21 analogue
1 (0–100 mg ml”1) and (B) NAS-91 analogue
15 (0–100 mg ml”1) were titrated into the M.
bovis BCG/pVV16 cultures at an OD600 of 0.4
prior to labelling with 1 mCi (37 kBq)
[1,2-14C]acetate ml”1 for 8 h. [14C]FAMEs
and [14C]MAMEs were extracted and resolved
by TLC. An equivalent aliquot (20 ml) of the
resulting solution of FAMEs and MAMEs was
subjected to TLC using silica gel plates (5735
silica gel 60F254; Merck), developed in pet-
roleum ether/acetone (95 : 5, v/v).
Autoradiograms were produced by overnight
exposure to Kodak X-Omat AR film to reveal
14C-labelled FAMEs and MAMEs.
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pVV16-Rv0636 FAS-II extract showed resistance to these
analogues. Analogues 13–15 also showed good whole-cell
activity against whole-cell M. bovis BCG/pVV16, providing
further evidence that these analogues would form a good
basis to generate a secondary library of NAS-91 analogues.
Effects of NAS-21 and NAS-91 analogues on
FAME and MAME synthesis
M. bovis BCG/pVV16 was grown in the presence of the
NAS analogues at various concentrations, followed by
[1,2-14C]acetate labelling and analysis by TLC separation of
FAMEs and MAMEs. An example of the results, for
analogues 1 and 15, is shown in Fig. 2. There was a decrease
in the incorporation of radioactivity into FAMEs and
MAMEs in the presence of NAS-21, analogues 1 and 15.
Since analogues 1 and 15 were shown not to inhibit FAS-I
(data not shown), the experiment was repeated; equal
counts were loaded and the TLC profiles of FAMEs and
MAMEs reanalysed (Fig. 3A, D). It is clear from this
analysis that analogues 1 and 15 only inhibit the synthesis
of a- and keto-MAMEs and not that of FAMEs (Fig. 3),
consistent with the earlier in vitro data (Tables 1 and 2). As
an additional control the synthesis of cell envelope lipids
was also examined (Fig. 3). Analogues 1 and 15 again do
not inhibit general fatty acid synthesis as the synthesis of
PGL (Fig. 3B, E) and phospholipids (Fig. 3C, F) remains
unaffected. Resistance was also observed upon the over-
expression of pVV16-Rv0636, supporting the earlier MIC99
and in vitro studies and thereby strengthening the evidence
that these analogues target Rv0636 (Fig. 2). Similar results
were observed with the other active analogues (2, 4, 13, 14
and 16).
Concluding remarks
In conclusion, no activity was observed against FAS-I for
either NAS-21 or NAS-91. In general, all the analogues
showed in vitro activity against FAS-II extracts, and the
Rv0636-overexpressing strain carrying pVV16-Rv0636
showed a marked increase in resistance. Whole-cell
FAME and MAME analysis for most analogues demon-
strated a decrease in both mycolic acid and fatty acid
biosynthesis. Interestingly, this effect of the analogues was
also reduced in M. bovis BCG/pVV16-Rv0636, thus further
implicating Rv0636 as the target for these FabZ dehydratase
inhibitors. The present study extends the initial findings of
Gratraud et al. (2008), who did not perform FAS-I and
FAS-II in vitro enzyme studies, using NAS-21 and NAS-91
to examine mycolate inhibition directly. Although the
study of Gratraud et al. (2008) demonstrated that NAS-21
and NAS-91 also inhibited oleate biosynthesis it is clear
that this represents a secondary target since it is non-
essential, in contrast to Rv0636, which has been shown to
Fig. 3. TLC-autoradiography ofM. bovis BCG
lipids after NAS-21 and NAS-91 analogue
treatment. (A, D) Analysis of FAMEs and
MAMEs following treatment with NAS-21
analogue 1 (20 mg ml”1) and NAS-91 ana-
logue 15 (15 mg ml”1) and resolved by TLC
using equal counts (50 000 c.p.m.) as
described in Methods. Lipid extractions were
performed as described by Dobson et al.
(1985) and a 50000 c.p.m. aliquot analysed
using silica gel plates (5735 silica gel 60F254;
Merck). (B, E) Phenolic glycolipids (PGL) were
identified by 2D TLC [direction 1, chloroform/
methanol (94 : 4, v/v); direction 2, toluene/
acetone (80 : 20, v/v)]. (C, F) Phospholipids
(P), phosphatidylinositol (PI), acyl-phosphati-
dylinositol dimannoside (Ac1PIM2) and diacyl-
phosphatidylinositol dimannoside (Ac2PIM2)
were identified by 2D TLC [direction 1,
chloroform/methanol/water (60 : 30 : 6, by
vol.); direction 2, chloroform/acetic acid/
methanol/water (40 : 25 : 3 : 6, by vol.)].
Autoradiograms were produced by overnight
exposure to Kodak X-Omat AR film to reveal
14C-labelled FAMEs, MAMEs and lipids.
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be essential (Brown et al., 2007a). In comparison to the
FAS-II flavonoid inhibitors (Brown et al., 2007b), our
NAS-21 and NAS-91 analogues demonstrated a marked
enhancement in activity; in some cases an eightfold
increase is observed. Therefore NAS-21 and NAS-91
analogues represent good candidates for further devel-
opment of drugs targeting the mycobacterial FAS-II
dehydratase. However, to fully establish the potential
therapeutic properties of NAS-21 and NAS-91, their in
vitro activity against the heterodimers Rv0635-Rv0636
(HadAB) and Rv0636-Rv0637 (HadBC) must be also
evaluated. The recent development of an in vitro assay
for the FAS-II dehydratase activity (Sacco et al., 2007) will
help us to better understand the inhibitory activity of these
compounds.
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